What you really need to do is you need to apply analytics and deep learning to that data to convert it to knowledge," Duffy said. Keith Higgins, FogHorn's vice president of marketing, said FogHorn ...

Citizens JMP initiated coverage of Foghorn Therapeutics (FHTX) with an Outperform rating and $9 price target Foghorn is a clinical-stage biotechnology company focused on developing novel therapies ...

April 15, 2025 (GLOBE NEWSWIRE) -- Foghorn ® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting ...